GR-MD-02 (a galectin-3 inhibitor) is currently in clinical trials to evaluate its usefulness in cancer patients with melanoma, NSCLC, and squamous cell head and neck cancer (NCT02117362, NCT02575404). The gene discussed is LGALS3; the disease is non-small cell lung carcinoma.